Canon Medical Systems announced that the U.S. Food & Drug Administration (FDA) has cleared its Compressed SPEEDER technology for use in the company’s Vantage Orian 1.5T MRI system.
Canon Medical Systems announced that the U.S. Food & Drug Administration (FDA) has cleared its Compressed SPEEDER technology for use in the company’s Vantage Orian 1.5T MRI system.
The technology, which is also available on the Vantage Galan 3T MRI system, can help reduce overall MRI scan times by reconstructing full resolution images from under-sampled data and avoiding unfolding error artifacts. In addition, it can help capture higher resolution images in 2D Fast Spin Echo acquisitions.
Reduced scan time not only presents an advantage for patients who find it difficult to remain still during long scans, but it also allows for additional time for disinfection of MRI systems and imaging suites between patients as practices begin to return to more normal patient volumes.
Faced with new, stringent cleaning protocols, more complex patient appointment management and other changes to workflow, the Compressed SPEEDER technology may help ease some post-pandemic growing pains for radiology departments and practices as many work to adjust to the “new normal.”
Canon’s new technology is included in an updated version of the M-Power software available for the Vantage Orian 1.5T. The software comes standard with Windows 10 and cybersecurity functionality, including continuous updates from Microsoft and whitelisting functions which allow for access only to authorized applications and processes.
“In MR imaging, shortening scan times is vastly important for both the patient and physician,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc., in a statement. “With the help of Compressed SPEEDER along with Windows 10 on the Vantage Orian 1.5T MR system, healthcare providers can offer a quick, comfortable and safe experience for their patients.”
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.